Association between Body Mass Index and Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants: A New Piece of Evidence on the Obesity Paradox from China
- PMID: 35394582
- DOI: 10.1007/s10557-022-07332-0
Association between Body Mass Index and Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants: A New Piece of Evidence on the Obesity Paradox from China
Abstract
Purpose: We conducted a multicenter real-world study in China to assess the association between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) taking direct oral anticoagulants (DOACs).
Method: This is a retrospective multicenter cohort study conducted in 15 centers in China. We collected demographic information through the hospital information system and obtained clinical events through follow-up visits to patients or relatives. Clinical outcomes include major, minor, total bleeding, thromboembolism, and all-cause death.
Result: A total of 6164 patients with non-valvular AF (NVAF) were included in this study. The incidence of major bleeding in patients with NVAF differed significantly by BMI category (P < 0.001), with 5.2% in the underweight group, 2.6% in the normal group, 1.4% in the overweight group, 1.1% in the obese I group, and 1.3% in the obese II group. There was no significant difference in minor, total bleeding, and thrombosis in the five groups (P = 0.493; P = 0.172; P = 0.663). All-cause death was significantly different among the five groups (P < 0.001), with 8.9% in the underweight group, 6.3% in the normal group, 4.8% in the overweight group, 2.2% in the obese I group, and 0.4% in the obese II group. High BMI was negatively associated with major bleeding (OR = 0.353, 95% CI 0.205-0.608), total bleeding (OR = 0.664, 95% CI 0.445-0.991), and all-cause death (OR = 0.370, 95% CI 0.260-0.527).
Conclusion: In patients with NVAF treated with DOACs, higher BMI was associated with lower major bleeding and better survival. BMI was a negative correlate of total bleeding, but not minor bleeding and thrombosis.
Keywords: Atrial fibrillation; Bleeding; Body mass index; Direct oral anticoagulation; Thrombosis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants.Heart Rhythm. 2017 Apr;14(4):501-507. doi: 10.1016/j.hrthm.2016.12.036. Epub 2016 Dec 29. Heart Rhythm. 2017. PMID: 28042092
-
Association between body mass index and long-term clinical outcomes in patients with non-valvular atrial fibrillation taking oral anticoagulants.Heart Vessels. 2023 Apr;38(4):551-561. doi: 10.1007/s00380-022-02194-w. Epub 2022 Nov 4. Heart Vessels. 2023. PMID: 36331618
-
Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation.Stroke. 2021 Jan;52(2):521-530. doi: 10.1161/STROKEAHA.120.030356. Epub 2021 Jan 11. Stroke. 2021. PMID: 33423512
-
The impact of underweight and obesity on outcomes in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis on the obesity paradox.Clin Cardiol. 2021 May;44(5):599-608. doi: 10.1002/clc.23593. Epub 2021 Mar 26. Clin Cardiol. 2021. PMID: 33769583 Free PMC article.
-
Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis.Am J Cardiovasc Drugs. 2020 Feb;20(1):51-60. doi: 10.1007/s40256-019-00362-4. Am J Cardiovasc Drugs. 2020. PMID: 31342343
Cited by
-
Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study.Thromb J. 2023 Apr 5;21(1):37. doi: 10.1186/s12959-023-00483-6. Thromb J. 2023. PMID: 37016388 Free PMC article.
-
The "obesity paradox" in patients with atrial fibrillation: Insights from the Gulf SAFE registry.Front Cardiovasc Med. 2022 Nov 30;9:1032633. doi: 10.3389/fcvm.2022.1032633. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36531711 Free PMC article.
-
Efficacy, safety, and bleeding risk factor analysis of oral anticoagulants in AF patients ≥ 65 years of age: a multicenter retrospective cohort study.BMC Geriatr. 2025 Mar 27;25(1):203. doi: 10.1186/s12877-025-05838-4. BMC Geriatr. 2025. PMID: 40148760 Free PMC article.
-
Direct oral anticoagulants and the risk of adverse clinical outcomes among patients with different body weight categories: a large hospital-based study.Eur J Clin Pharmacol. 2024 Jan;80(1):163-173. doi: 10.1007/s00228-023-03593-2. Epub 2023 Nov 18. Eur J Clin Pharmacol. 2024. PMID: 37978999 Free PMC article.
-
Fibrinaloid Microclots and Atrial Fibrillation.Biomedicines. 2024 Apr 17;12(4):891. doi: 10.3390/biomedicines12040891. Biomedicines. 2024. PMID: 38672245 Free PMC article. Review.
References
-
- Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;6(354):i4482. - DOI
-
- Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;2005(3):CD001927.
-
- Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines-CPG. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;14:1385–1413.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical